



## **Geneoscopy Expands Leadership Team to Support ColoSense™ Rollout and Advance Precision IBD Solutions**

**ST. LOUIS, Mo. – May 15, 2024** – [Geneoscopy, Inc.](#), a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, has appointed Matt Sargent as Chief Commercial Officer and Tyler Aldredge as Vice President of Operations to support the commercialization of ColoSense, which recently [received FDA approval](#) for colorectal cancer screening (CRC) in average-risk individuals over 45 years of age. Sargent and Aldredge will also help expand the company's RNA platform to inflammatory bowel disease (IBD) diagnostics, offering providers and patients a promising tool for predicting and monitoring therapeutic effectiveness.

“We are pleased to welcome Matt and Tyler to the Geneoscopy team at such a pivotal time for the company,” said Andrew Barnell, Geneoscopy’s co-founder and Chief Executive Officer. “Matt’s proven experience commercializing oncology diagnostic products and Tyler’s expertise in operational process and management will be critical as we accelerate toward bringing ColoSense to market and hit several key clinical and development milestones with IBD.”

"As I step into this new role, I look forward to collaborating with our talented team and partners to realize the full potential of our innovative RNA technology and bring valuable solutions to patients and providers,” said Sargent. “With our focus on advancing ColoSense and expanding precision diagnostics for IBD, we are poised to make a meaningful impact in improving outcomes for the [60-70 million Americans](#) suffering from GI diseases.”

Sargent brings 20 years of experience leading high-performance commercial teams in the oncology space. Most recently, he served as Chief Business Officer at Harbinger Health, responsible for business development related to the company’s blood-based cancer early detection test. Before Harbinger Health, he was Vice President of Commercial Oncology at Hologic, responsible for sales, commercial strategy, and business development for the CLIA oncology diagnostics service business, following Hologic’s acquisition of Biotheranostics, where he served as Chief Commercial Officer.

Aldredge brings more than 30 years of leadership, operations management, and operational quality experience across a range of multi-site laboratories and facilities, along with extensive proficiency in process development and laboratory set-up, scale-up, and automation. Before joining Geneoscopy, Aldredge served as Vice President of Lab Operations, Facilities, and Real Estate with Bluerock Therapeutics. He is a member of the Society for Laboratory Automation and Screening and serves on the Lab-of-the-Future Committee.

Sargent and members of Geneoscopy's leadership team will attend [Digestive Disease Week 2024](#) in Washington, D.C., May 18-21 (booth #1407). Additionally, two posters will be presented at the meeting, demonstrating the capabilities of Geneoscopy's stool-based RNA platform:

- *Stool-derived eukaryotic RNA assay approximates disease activity index and predicts therapeutic response in patients with Crohn's disease on advanced therapies*
  - Date & Time: May 18, 2024, from 12:30 PM to 1:30 PM
- *Development of a second-generation multi-target stool RNA test (ColoSense 2.0) for colorectal cancer screening*
  - Date & Time: May 19, 2024, from 12:30 PM to 1:30 PM

#### **About Geneoscopy, Inc.**

Geneoscopy Inc. is a life sciences company focused on developing diagnostic tests for gastrointestinal health. Leveraging its proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform, Geneoscopy's mission is to empower patients and providers to transform gastrointestinal health through innovative diagnostics. The company's [FDA-approved ColoSense™ test](#) uses a proprietary RNA-based platform to screen for colorectal cancer and advanced adenomas for average-risk individuals over the age of 45. In partnership with leading universities and biopharmaceutical companies, Geneoscopy is also developing diagnostic tests for treatment selection and therapy monitoring in other GI disease areas. For more information, visit [www.geneoscopy.com](http://www.geneoscopy.com) and follow the company on [LinkedIn](#).

###

#### **Media:**

Andrea Sampson  
Sampson Public Relations Group  
[asampson@sampsonprgroup.com](mailto:asampson@sampsonprgroup.com)

#### **Investor Relations:**

Carrie Mendivil / Ji-Yon Yi  
Gilmartin Group  
[investors@geneoscopy.com](mailto:investors@geneoscopy.com)